| DC Field | Value | Language |
|---|
| dc.contributor.author | Gutul, Catalina | - |
| dc.date.accessioned | 2020-07-09T14:56:28Z | - |
| dc.date.available | 2020-07-09T14:56:28Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | GUTUL, Catalina. Correlative aspects of ovarian reserve and severity of polycystic ovary syndrome. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 76-77. | en_US |
| dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf | - |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11199 | - |
| dc.description | Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
| dc.description.abstract | Introduction. Polycystic ovary syndrome is primarily diagnosed in the early years of the fertile
period. Clinical expressions are variable, and may include oligo/anovulation, hyperandrogenism
(clinical or biochemical) and ultrasonographic polycystic ovary signs, according to the
Rotterdam criteria. All of these complexes are the cause of anovulatory infertility (Fanchin R1,
Schonäuer LM, Righini C, Human Reproduction, 2003, Farquar C., Lilford RJ, Marjoribanks J.,
Chochrane Database Syst. Rev., 2007) A variety of clinical and experimental studies are directed
to the PCOS events. However, the etiology of the syndrome remains obscure, and the variability
of phenotypic expression continues to be a challenge both from the clinical and research point of
view (Leelan L., Acharya U., J. Obstet, Gynaecol., 2009). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | MedEspera | en_US |
| dc.subject | polycystic ovary syndrome | en_US |
| dc.subject | anti-Müllerian hormone | en_US |
| dc.title | Correlative aspects of ovarian reserve and severity of polycystic ovary syndrome | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | MedEspera 2018
|
